Michael B Murphy
Overview
Explore the profile of Michael B Murphy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1958
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murphy M, Vitale L, ONeill T, Maurer D, Malenchek L, Crocker A, et al.
Allergy
. 2025 Feb;
PMID: 39976188
Background: Mast cells (MCs) respond to an array of allergens that drive allergic and inflammatory diseases. Stem cell factor (SCF), the ligand for the receptor KIT, is required for MC...
2.
Belcher P, Moberg A, Murphy M
SLAS Discov
. 2024 Nov;
29(8):100192.
PMID: 39488330
The number of peer-reviewed publications that feature biosensor data increases every year. A search of PubMed using common technique terminology, including bio-layer interferometry (BLI), surface plasmon resonance (SPR) and grating-coupled...
3.
Murphy M, Kelly B
J Am Coll Emerg Physicians Open
. 2024 Oct;
5(5):e13286.
PMID: 39421271
No abstract available.
4.
Wright K, Jiang H, Xia W, Murphy M, Boronina T, Nwafor J, et al.
ACS Bio Med Chem Au
. 2023 Dec;
3(6):516-527.
PMID: 38144259
Na1.7, the neuronal voltage-gated sodium channel isoform, plays an important role in the human body's ability to feel pain. Mutations within Na1.7 have been linked to pain-related syndromes, such as...
5.
Alvarado D, Maurer M, Gedrich R, Seibel S, Murphy M, Crew L, et al.
Allergy
. 2022 Feb;
77(8):2393-2403.
PMID: 35184297
Background: Mast cells (MC) are powerful inflammatory immune sentinel cells that drive numerous allergic, inflammatory, and pruritic disorders when activated. MC-targeted therapies are approved in several disorders, yet many patients...
6.
Hwang M, Miller M, Thirawatananond P, Douglass J, Wright K, Hsiue E, et al.
Nat Commun
. 2021 Sep;
12(1):5271.
PMID: 34489470
Chimeric antigen receptor (CAR) T cells have emerged as a promising class of therapeutic agents, generating remarkable responses in the clinic for a subset of human cancers. One major challenge...
7.
Hsiue E, Wright K, Douglass J, Hwang M, Mog B, Pearlman A, et al.
Science
. 2021 Mar;
371(6533).
PMID: 33649166
(tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as , are not yet available. Here, we describe the...
8.
Douglass J, Hsiue E, Mog B, Hwang M, DiNapoli S, Pearlman A, et al.
Sci Immunol
. 2021 Mar;
6(57).
PMID: 33649101
Mutations in the oncogenes occur in multiple cancers, and ways to target these mutations has been the subject of intense research for decades. Most of these efforts are focused on...
9.
Meuser M, Murphy M, Rashad A, Cocklin S
Molecules
. 2018 Aug;
23(8).
PMID: 30081466
The entry of HIV-1 into permissible cells remains an extremely attractive and underexploited therapeutic intervention point. We have previously demonstrated the ability to extend the chemotypes available for optimization in...
10.
Techtmann S, Colman A, Murphy M, Schackwitz W, Goodwin L, Robb F
Front Microbiol
. 2018 Jul;
9:1016.
PMID: 30013517
[This corrects the article on p. 147 in vol. 2, PMID: 21808633.].